Mohammad Karim Rezai

Dr. Mohammad Karim Rezai is the head of research and development at the first Iranian company producing a generic lung cancer medication. He has been in the news for discussing the significant advancements in the production of a new medication for pulmonary fibrosis, which is now available in Iran at a fraction of the cost of its foreign counterpart. Under his leadership, the company has focused on high-tech pharmaceuticals, particularly those that require advanced technical knowledge and have limited global manufacturers. Dr. Rezai emphasizes the importance of accessibility to such medications for Iranian patients, as well as the challenges posed by international sanctions on the pharmaceutical industry.